Venous Thrombosis Clinical Trial
Official title:
Intermittent Pneumatic Compression (IPC) of the Foot Versus Geko™ Neuromuscular Electrostimulation (NMES): Comparison of Lower Limb Circulation Following Elective Total Hip Replacement (THR)
Verified date | October 2017 |
Source | Hampshire Hospitals NHS Foundation Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of this pilot study was to assess venous flow parameters in patients following total hip arthroplasty, comparing an intermittent pneumatic compression foot device with a portable neuromuscular electrostimulator device. Assessments were performed in a single sitting before hospital discharge, between days 1 to 4 post operatively. The total duration of participation for each patient who completed the study was approximately 2.5 hours.
Status | Completed |
Enrollment | 10 |
Est. completion date | February 19, 2014 |
Est. primary completion date | February 19, 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - patients undergoing primary THA, - in good general health and fitness, - age 18 years or over - able to provide written informed consent. Exclusion Criteria: - Are requiring hip revision surgery - Previous or current diagnosis of deep vein thrombosis (DVT) or pulmonary embolism (PE). - History or signs of significant haematological disorders (especially in relation to clotting or coagulation) or thrombophlebitis. - Peripheral arterial disease, clinically significant varicose veins or lower limb ulceration or ischemia. - Recent surgery within the last 3 months (such as abdominal, gynaecological, hip or knee replacement). - Recent trauma to lower limb. - Chronic Obesity (BMI Index >40kg/m2). - Pregnancy. - Significant history of following diseases i. Cardiovascular: Recent MI (< 6 months) ii. Percutaneous Coronary Intervention (PCI) with stent (< 3 months for Bare metal stent (BMS) and < 12 months for Drug Eluding Stent (DES) iii. Moderate to severe CCF, uncontrolled AF iv. Neurological: Stroke, Hemiplegia/Paraplegia, Myopathies v. Renal: Moderate to severely impaired renal function vi. Hepatic: Moderate to severely impaired hepatic function vii. Psychiatric disorders viii. Dermatological conditions affecting lower limbs - On LMWH/Heparin (Prophylactic/therapeutic doses) or Warfarin or warfarin stopped recently and replaced by LMWH/ Heparin - Long term steroid use with dermatological changes - A pulse rate of less than 40 beats/minute - A sitting systolic blood pressure >180 and <100 mmHg and/or a sitting diastolic pressure of >100 mmHg. - Participation in any clinical study during the eight (8) weeks preceding the screening period - THR done for hip fracture |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Hampshire Hospitals NHS Foundation Trust | Firstkind Ltd |
Warwick DJ, Shaikh A, Gadola S, Stokes M, Worsley P, Bain D, Tucker AT, Gadola SD. Neuromuscular electrostimulation viathe common peroneal nerve promotes lower limb blood flow in a below-kneecast: A potential for thromboprophylaxis. Bone Joint Res. 2013 Sep 2;2(9):179-85. doi: 10.1302/2046-3758.29.2000176. Print 2013. — View Citation
Williams KJ, Moore HM, Davies AH. Haemodynamic changes with the use of neuromuscular electrical stimulation compared to intermittent pneumatic compression. Phlebology. 2015 Jun;30(5):365-72. doi: 10.1177/0268355514531255. Epub 2014 Apr 10. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Venous flow at baseline | Measured within the superficial femoral vein using ultrasound | "t0" - 30 minutes to include the ultrasound assessment, performed between days 1 and 4 post operatively | |
Primary | Venous flow after application of device 1 | Measured within the superficial femoral vein using ultrasound | "t1" - 90 minutes to include the ultrasound assessment | |
Primary | Venous flow after application of device 2 | Measured within the superficial femoral vein using ultrasound | "t2" - 150 minutes to include the ultrasound assessment | |
Secondary | Patient satisfaction with device 1 | verbal rating score: 1 extremely comfortable, 2 comfortable, 3 uncomfortable, 4 very uncomfortable, 5 extremely uncomfortable. | Immediately after completion of the ultrasound assessment for device 1, at "t1" - 90 minutes | |
Secondary | Patient satisfaction with device 2 | verbal rating score: 1 extremely comfortable, 2 comfortable, 3 uncomfortable, 4 very uncomfortable, 5 extremely uncomfortable. | Immediately after completion of the ultrasound assessment for device 2, at "t2" - 150 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02567903 -
Tourniquet Study: A Clinical Trial Into the Effect of Tourniquet Use on the Coagulation System
|
N/A | |
Completed |
NCT02247414 -
Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection
|
Phase 4 | |
Recruiting |
NCT02650453 -
Ongoing Registry of Deep Venous Reconstructions
|
N/A | |
Completed |
NCT02065388 -
Pharmacogenetic Dosing of Warfarin
|
Phase 3 | |
Completed |
NCT00839657 -
Clarification of Optimal Anticoagulation Through Genetics
|
Phase 3 | |
Terminated |
NCT00872079 -
Personalized Warfarin Dosing by Genomics and Computational Intelligence
|
N/A | |
Terminated |
NCT00521885 -
Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients
|
N/A | |
Completed |
NCT02892565 -
Hypercoagulable Phenotype by Thrombinography (in Presence of C Protein Dynamic Inhibitory System)
|
N/A | |
Completed |
NCT00346424 -
Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters
|
Phase 3 | |
Active, not recruiting |
NCT04349189 -
Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait
|
||
Recruiting |
NCT02238444 -
Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy
|
Phase 4 | |
Recruiting |
NCT02597218 -
Incidence of Venous Thromboembolic Disease and Portal Vein Thrombosis After Hepatectomy. A Cohort Study.
|
||
Completed |
NCT00986154 -
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
|
Phase 3 | |
Completed |
NCT00246025 -
A Study of BIBR 1048 in Prevention of Venous Thromboembolism in Patients With TKR Surgery.
|
Phase 2 | |
Completed |
NCT00097357 -
BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery
|
Phase 2/Phase 3 | |
Completed |
NCT04645550 -
Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy(ESAWAAPT)
|
Phase 4 | |
Recruiting |
NCT02264743 -
Oral Verses Patch Trial In Menopausal Women - Individualisation of Oestrogen Therapy
|
Phase 4 | |
Completed |
NCT01482273 -
Ultrasound-enhanced Thrombolysis Versus Standard Catheter Directed Thrombolysis for Ilio-femoral Deep Vein Thrombosis
|
N/A | |
Recruiting |
NCT01252420 -
Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis
|
Phase 4 | |
Completed |
NCT01145859 -
Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects
|
Phase 1 |